A GUIDE TO THIS REFLECTIONS B RESEARCH STUDY IF YOU RE FIGHTING BREAST CANCER, YOU RE NOT ALONE
|
|
- Kellie Beasley
- 6 years ago
- Views:
Transcription
1 A GUIDE TO THIS REFLECTIONS B RESEARCH STUDY IF YOU RE FIGHTING BREAST CANCER, YOU RE NOT ALONE
2 Do you have breast cancer that has spread to outside the breast? Has your tumor tested positive for the HER2 receptor? Have you not received treatment since the tumor has spread? What are clinical studies? You may be interested in a clinical research study in patients with HER2-positive metastatic breast cancer (MBC). This brochure will tell you a little about this REFLECTIONS B study, as well as clinical studies in general. If you have any questions, or would like to discuss the study further, please contact the study site staff using the details provided on the back cover of this brochure. Clinical studies involve research of investigational drugs in people who volunteer to participate in them. All medications are investigated in a number of carefully controlled and highly regulated clinical studies that are designed to answer questions about the safety and benefits of an investigational medication. Every clinical study must be reviewed by the regulatory authorities and independent ethics committees in all countries that the study will be conducted in prior to the study being started. Physicians and their research staff oversee these studies. Choosing to take part in a clinical trial is an important personal decision. By answering specific questions, clinical studies help us find alternative medicines to current options. Thousands of people all around the world take part in clinical studies every year. Every volunteer is important because without these individuals, the development of medicines simply would not be possible. Why is this REFLECTIONS B study necessary? A number of different medicines are available for the treatment of HER2-positive breast cancer. One such treatment is called Herceptin (trastuzumab), which has shown to be effective in patients with HER2- positive breast cancer in the early stage and also after it has spread. Trastuzumab is a biologic drug that has a large and complicated structure. A biosimilar is a drug that has a structure that is highly similar to the original drug and has been shown to have a similar benefit and safety profile to the original drug. We are developing an investigational drug that has a structure that is similar to trastuzumab and is now being tested in clinical trials. This REFLECTIONS B study is being conducted as part of a larger research program to develop a potential biosimilar for trastuzumab for individuals with HER2-positive breast cancer. The REFLECTIONS B study will evaluate whether the investigational drug has a similar benefit and safety profile compared to the known profile for trastuzumab. Who can take part in this REFLECTIONS B study? We are looking for female patients with HER2-positive metastatic breast cancer to take part in this REFLECTIONS B study. In particular, eligible patients must: Have breast cancer that has spread to outside the breast Have a tumor that tested positive for the HER2 receptor Not received treatment since the tumor has spread There are some additional medical criteria that must be met to join the study. Before joining, all patients would need to have a number of screening tests to make sure the study is suitable for them.
3 What study Drug would I get? If you are eligible and choose to join this REFLECTIONS B study, you will be assigned to one of two study groups. To make sure the study is completely fair, the study group to which you are assigned will be decided by chance (at random). Neither you nor the study doctor will know which study drug you are receiving. This is done to ensure the results of the study cannot be unfairly influenced by anyone. Notes Please use the following space to make notes or write down any questions you have for the study site staff. Participants assigned to one of the groups will be given the original trastuzumab, while participants assigned to the other group will be given the potential biosimilar to trastuzumab. All patients in the study will also receive treatment with paclitaxel, a chemotherapy agent that is commonly used in combination therapy for breast cancer. The REFLECTIONS B study will use a study drug dosing and assessment schedule that is typical for this setting. You would receive weekly intravenous infusions (a solution administered into your vein) of study drug for up to 8 months, with the option to continue with this regimen (either trastuzumab or trastuzumab biosimilar) or less frequent dosings for as long as you and your study doctor agree you are benefiting. On the days of study drug dosing the infusion time may take more than 4 hours. You may choose to bring a book or magazine with you to help to pass the time. What would I need to do? During the study, you would need to visit the study center weekly at first for study drug dosing and assessments. The frequency may reduce to every 3 weeks later in your participation in the study depending on the options you and your study doctor choose. An outline of the different procedures required during the different study visits is given below: Visit Screen Cycle 1 Dosing period Cycles with weekly treatment Cycles with dosing every 3 weeks End of study drug dosing Cycle day 28 Days Prior Physical examination X X X X X X X Blood work X X X X X X X X X Heart assessments X Weeks 9, 17, 25, 33, 41 and 53, then every 12 weeks X Study drug infusions X X X X X X X X X X Tumor assessments X Weeks 9, 17, 25, 33, 41 and 53, then every 12 weeks Follow-up 6 months beyond study drug dosing It is important that you attend each of your scheduled appointments.
4 Is there anything else that I should know? As with most things, there may be some risks and discomforts involved in taking part in a clinical study. However, the safety of participants is monitored during every stage of the process: Before the study Every study is closely regulated and must be reviewed by an independent ethics committee (IEC) / Institutional Review Board (IRB), which is a committee that has been formally designated to monitor and review biomedical and research involving humans. The committee is made up of healthcare/research professionals and non-medical members who have the qualifications and experience to review the ethics, science, and medical aspects of the clinical study and is responsible to protect the rights, safety and well being of human research subjects. If you decide to join, the study will be carefully explained to you and you will be given the chance to ask questions. You will then be asked to sign an Informed Consent Document to show you understand and agree to what the study involves. During the study While the study is ongoing, a specialist team of study doctors and nurses at the study center will monitor your health closely. This study will be blinded. This means that the volunteers and the researchers conducting and overseeing the trial will not be made aware of which study drug you will be receiving until the study is completed. This information is available in case of emergency. Like all medicines, trastuzumab and paclitaxel can cause side effects, although not everybody gets the same side effects. Most side effects are mild to moderate but some may be serious and require treatment or hospitalization. Reactions during or soon after trastuzumab or paclitaxel infusions can occur. These can include allergic type reactions, chills, fever, flu-like symptoms and other events. Rarely, infusion reactions can become serious. Other side effects can include heart problems during or after dosing, low blood cell counts, feeling tired, hair loss, numbness in your hands or feet (neuropathy), joint or muscle pain, nausea, vomiting and other effects. The study team would discuss with you all of the side effects that could be anticipated before you make the decision to participate in the study. If you join the study and change your mind at a later date, you are free to leave the study at any time. No financial incentive is offered to participants, but you may be reimbursed for travel and expenses. The study drugs and procedures are provided at no cost. Also, all patients participating in this REFLECTIONS B study will receive study-related care during the study, and their health will be monitored throughout. Taking part in a study doesn t guarantee your health will improve. Because breast cancer is a long-term condition, you should ensure that you have regular contact with medical professionals. Keep all appointments with your healthcare team, and discuss any changes you have noticed in your symptoms. What should I do now? If you are interested in joining this REFLECTIONS B study or would like further information, please contact the study site staff on the number provided on the back cover of this brochure. If both you and your study doctor think that you may be eligible for this REFLECTIONS B study, you will be asked to sign an informed consent form to show that you: Understand what the study involves Agree to take part. You will then be invited for a screening visit to ensure that you fully meet the requirements of the study. Thank you for your time and interest in this REFLECTIONS B study.
5 B _29JUL2013_US_ENG_Brochure_V2_10SEP2013
Learning about Clinical Trials
Learning about Clinical Trials A Guide for Individuals and Their Loved Ones INTRODUCTION Clinical trials help researchers answer important medical questions, providing information that may help with the
More informationClinical trials patient-education brochure
Released November 2005 Revised January 2008 Revised March 2012 Revised July 17, 2017 Clinical trials patient-education brochure Roslyn Mannon, MD David Rothstein, MD Maria Luisa Alegre, MD, PhD Giorgio
More informationBrain Tumour Australia Information FACT SHEET 22 Clinical Trials: Questions and Answers
FACT SHEET 22 Clinical Trials: Questions and Answers What is a clinical trial? Clinical trials are research studies that answer scientific questions and try to find better ways to prevent, screen for,
More informationMyeloma XII (ACCoRd) Myeloma Infosheet Series. Clinical trials and novel drugs Infoline:
Myeloma XII (ACCoRd) This Infosheet provides information about what the Myeloma XII clinical trial is, why it is taking place and what is involved if patients decide to take part in the trial. This Infosheet
More informationFACTS YOU NEED TO KNOW UNITED STATES OF AMERICA
CLINICAL TRIALS BROCHURE FACTS YOU NEED TO KNOW Thousands of men across the United States suffer from the difficult effects of prostate cancer and often undergo treatment that does not produce optimal
More informationFREQUENTLY ASKED QUESTIONS
CLINICAL TRIALS FREQUENTLY ASKED QUESTIONS PARTICIPATING IN A CLINICAL TRIAL What is a clinical trial? Clinical trials are research studies that involve people. Through clinical trials, researchers find
More informationAbout Clinical Trials
About Clinical Trials A guide for people with CF and their families INSIDE Who Can Participate in a Clinical Trial? Clinical Research Basics Who Is Involved in Clinical Research? Informed Consent Your
More informationSTN: BL /5234 HSTCL PAS April 14, 2009
Rx Only MEDICATION GUIDE REMICADE (Rem-eh-kaid) (infliximab) Read the Medication Guide that comes with REMICADE before you receive the first treatment, and before each time you get a treatment of REMICADE.
More informationCelldex Compassionate Use Policy
Celldex Compassionate Use Policy Introduction Currently, none of Celldex s investigational products are available for compassionate use given their early stage of clinical development. The policy outlined
More informationCLINICAL TRIALS: WHAT YOU NEED TO KNOW
CLINICAL TRIALS: WHAT YOU NEED TO KNOW www.kidney.org National Kidney Foundation's Kidney Disease Outcomes Quality Initiative Did you know that the National Kidney Foundation's Kidney Disease Outcomes
More informationClinical trials for brain tumours
Clinical trials for brain tumours The purpose of clinical trials for brain tumour patients is to gain a better understanding of these tumours and improve diagnosis and treatment. Some trials also seek
More informationGenentech, Inc., its research partners, collaborators, assignees, licensees or designees. Invitation to Participate
CONSENT AND RESEARCH AUTHORIZATION TO DONATE BLOOD AND TISSUE SAMPLES FOR FUTURE RESEARCH PURPOSES YALE UNIVERSITY SCHOOL OF MEDICINE YALE-NEW HAVEN HOSPITAL 200 FR. 4 Study Title: An Open-Label, Phase
More informationMEDICATION GUIDE REMICADE (Rem-eh-kaid) (infliximab)
MEDICATION GUIDE REMICADE (Rem-eh-kaid) (infliximab) Read the Medication Guide that comes with REMICADE before you receive the first treatment, and before each time you get a treatment of REMICADE. This
More informationMEDICATION GUIDE REMICADE (Rem-eh-kaid) (infliximab) What is the most important information I should know about REMICADE?
MEDICATION GUIDE REMICADE (Rem-eh-kaid) (infliximab) Read the Medication Guide that comes with REMICADE before you receive the first treatment, and before each time you get a treatment of REMICADE. This
More informationA LOOK AT WHAT S INSIDE
ADVOCACY TOOLKIT A LOOK AT WHAT S INSIDE WELCOME... 3 RESOURCES FOR YOU... 4 Why Get Involved?... 5 Key Messages... 6 Ways to Engage... 7 RESOURCES FOR YOUR MEMBERS... 8 Fact Sheet: Did You Know?... 9
More informationInformation and resources for African Americans living with multiple myeloma and their caregivers
For African Americans living with Multiple Myeloma Information and resources for African Americans living with multiple myeloma and their caregivers Standing in the Gaap: An initiative created to help
More informationRelated Donor Informed Consent to Participate in Research
Related Donor Informed Consent to Participate in Research This is an informed consent document for a research study that your family member is participating in. This document will inform you about the
More informationMEDICATION GUIDE RIBAVIRIN TABLETS Rx Only Read this Medication Guide carefully before you start taking ribavirin tablets and read the Medication
MEDICATION GUIDE RIBAVIRIN TABLETS Rx Only Read this Medication Guide carefully before you start taking ribavirin tablets and read the Medication Guide each time you get more ribavirin tablets. There may
More informationAbout Clinical Trials: What They Can Mean For You?
About Clinical Trials: What They Can Mean For You? Karl Cremer, PharmD and AnnKatrin Petersen, MD, MS January 25, 2012 ClinicalStudy.org Owned and operated by PRI, Inc. 5927 Balfour Court, Suite 201 Carlsbad,
More informationHEALTH CARE PROVIDER TOOLKIT
HEALTH CARE PROVIDER TOOLKIT A LOOK AT WHAT S INSIDE WELCOME... 3 RESOURCES FOR YOU AND YOUR STAFF... 4 Why Get Involved?... 5 Key Messages... 7 Ways to Engage... 8 Website/Blog Article... 9 Social Media
More informationSYMPTOM CONTROL? PEDIATRICS
IS YOUR CHILD READY FOR SYMPTOM CONTROL? PEDIATRICS For children ages 6-17 with moderately to severely active Crohn s disease or ulcerative colitis (UC) who haven t responded well to other therapies SELECTED
More informationCADTH CANADIAN DRUG EXPERT COMMITTEE FINAL RECOMMENDATION
CADTH CANADIAN DRUG EXPERT COMMITTEE FINAL RECOMMENDATION FILGRASTIM (Grastofil Apotex Inc.) Indications: Prevention or Treatment of Neutropenia Recommendation: The CADTH Canadian Drug Expert Committee
More informationTreatment strategies for relapsing and refractory myeloma
Treatment strategies for relapsing and refractory myeloma Dr Guy Pratt #MyelomaInfodays This talk will cover What is relapse and refractory myeloma Treatment options for relapse Treatment options for refractory
More informationClinical Trials: What You Need to Know
Clinical Trials: What You Need to Know Knowing all you can about clinical trials can help you feel better when deciding whether or not to take part in one. This guide addresses many basic questions and
More informationTreatment: Nutrition and Medication
INFLAMMATORY BOWEL DISEASE (IBD): CROHN S DISEASE Treatment: Nutrition and Medication While there is no cure for Crohn s disease, there are a number of options to help treat it. The goals of treatment
More informationMore Effective Treatments for Multiple Myeloma Convention Connection: American Society of Hematology Meeting December 2010 Dan Vogl, M.D.
More Effective Treatments for Multiple Myeloma Convention Connection: American Society of Hematology Meeting December 2010 Dan Vogl, M.D. Please remember the opinions expressed on Patient Power are not
More informationCLINICAL TRIALS AND MARKET RESEARCH
CLINICAL TRIALS AND MARKET RESEARCH AAKP's role in Clinical Trials and Market Research AAKP supports innovation in the kidney space. We are actively involved in market research - to share the patient voice
More informationPatient Handbook on Stem Cell Therapies
Patient Handbook on Stem Cell Therapies WWW.ISSCR.ORG WWW.CLOSERLOOKATSTEMCELLS.ORG Patient Handbook on Stem Cell Therapies Introduction We have all heard about the extraordinary promise that stem cell
More informationAndrew Schorr: Is there anything you ve been discussing that you d like to update people about now?
News from ASH: Advances in Bleeding Disorders ASH Conference Coverage December 8, 2008 Craig Kessler, M.D. Please remember the opinions expressed on Patient Power are not necessarily the views of our sponsors,
More informationvs Non-Medical Switching
January 2017 NON-MEDICAL SWITCHING While 21st Century medications represent some remarkable breakthroughs, they often come with high costs. As a result, many agencies are exploring ways to minimize drug
More informationIron Deficiency Anemia Information for patients and families
Iron Deficiency Anemia Information for patients and families Read this brochure to learn about: Iron Deficiency Anemia Oral Iron Supplementation Intravenous Iron What is iron deficiency? Iron deficiency
More informationGet know to us! Objectives. Clinical trial accrual is decreasing! Why is accrual to trials so low? Coordinating Pragmatic Trials
Clinical Research Week 2016 Coordinating Pragmatic Trials Get know to us! Carol Stober CRA & Sasha Mazzarello CRC Objectives Current Clinical Trial Model What is a Pragmatic Trial? What is REaCT? Integrated
More informationThe Importance of Participating in Clinical Trials in Alzheimer s Disease. Amanda G. Smith, M.D. Medical Director USF Health Byrd Alzheimer Institute
The Importance of Participating in Clinical Trials in Alzheimer s Disease Amanda G. Smith, M.D. Medical Director USF Health Byrd Alzheimer Institute First and foremost Clinical trials and studies are a
More informationDonor Informed Consent to Participate in Research
Donor Informed Consent to Participate in Research This is a consent form for a research study. This clinical trial is a research study to determine better treatment for patients with Multiple Myeloma (MM).
More informationYou ve Got the POWER! What You Should Know About Clinical Trials
You ve Got the POWER! What You Should Know About Clinical Trials Project I.M.P.A.C.T. (Increase Minority Participation and Awareness of Clinical Trials) We want to help you and your family use medical
More informationGenitope Corporation. Summary of MyVax Personalized Immunotherapy Phase 3 Clinical Trial Results
Genitope Corporation Summary of MyVax Personalized Immunotherapy Phase 3 Clinical Trial Results Introduction In December 27, Genitope Corporation ( Genitope ) obtained data indicating that its pivotal
More information1.4 Applicable Regulatory Requirement(s) Any law(s) and regulation(s) addressing the conduct of clinical trials of investigational products.
1.1 Adverse Drug Reaction (ADR) In the pre-approval clinical experience with a new medicinal product or its new usages, particularly as the therapeutic dose(s) may not be established: all noxious and unintended
More informationNanthealth Patient Informed Consent
Patient Informed Consent Why am I being asked to give consent? You are being asked to sign this consent form because you want to have a molecular/genomic analysis performed to help your physician understand
More informationLEARN. about. Please see Important Safety Information on pages 3-5 and enclosed full Prescribing Information.
LEARN about on pages 3-5 and enclosed 2 3? What is ZARXIO (filgrastim-sndz)? ZARXIO is a man-made form of granulocyte colony-stimulating factor (G-CSF) called filgrastim. G-CSF is a substance produced
More informationMyeloma treatment algorithm 1999
Outlook for myeloma patients has improved Treatment for relapsed and/or refractory myeloma Dr Guy Pratt Consultant Haematologist, Heart of England NHS Foundation Trust Senior Lecturer, University of Birmingham
More informationNational MS Society Information Sourcebook
National MS Society Information Sourcebook www.nationalmssociety.org/sourcebook Interferons The interferons are a group of natural proteins that are produced by human cells in response to viral infection
More informationGENENTECH PROVIDES UPDATE ON PIPELINE AGENTS AT THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY MEETING
NEWS RELEASE Media Contact: Krysta Pellegrino (650) 225-8226 Investor Contact: Diane Schrick (650) 225-1599 Advocacy Contact: Kristin Reed (650) 467-9831 GENENTECH PROVIDES UPDATE ON PIPELINE AGENTS AT
More informationOxford Newborn Care Unit. Palivizumab (Synagis ) for RSV Infection Information for parents and carers
Oxford Newborn Care Unit Palivizumab (Synagis ) for RSV Infection Information for parents and carers page 2 Why have we been given this information? Your baby has been identified as being likely to benefit
More informationimpact on a trial design and labeling
Genotyping-impact impact on a trial design and labeling Yoshiaki Uyama,, Ph.D. Office of New Drug III (PMDA) Benefit of Pharmacogenomics Improving benefit/risk ratio More safe, more effective Adjusting
More informationBeryllium Testing Information and Consent Form
Beryllium Testing Information and Consent Form What is the purpose of the beryllium testing in the NSSP? The main purpose of this beryllium testing is to determine whether or not former Department of Energy
More informationThe patient must address the treating physician directly if he/she has any questions or requires information regarding the test results.
Order Form 1. Ordering of the FoundationOne Service The FoundationOne Service comprises the genetic analysis of tumour tissue and the compilation of a comprehensive report on any mutations found in the
More informationDaratumumab (Darzalex )
Daratumumab (Darzalex ) This Horizons Infosheet contains information on daratumumab (also known as Darzalex), a drug being investigated for the treatment of myeloma. The Horizons Infosheet series provides
More informationVolunteering for Clinical Trials
Volunteering for Clinical Trials Volunteering for Clinical Trials When considering volunteering for a clinical trial, it is important to make an informed decision. Below are answers to frequently asked
More informationConsiderations and reflections concerning implementation of biosimilar MABs in the clinic - focus on trastuzumab
Considerations and reflections concerning implementation of biosimilar MABs in the clinic - focus on trastuzumab Head of Department of Clinical Pharmacology, Bispebjerg and Frederiksberg Hospital PhD MD
More informationCompulsory licensing of patents for the cancer drug T-DM1 Manon Ress KEI May 21, 2015 WHA 68, KEI side event on compulsory licensing
Compulsory licensing of patents for the cancer drug T-DM1 Manon Ress KEI May 21, 2015 WHA 68, KEI side event on compulsory licensing CL The availability of compulsory licences in relation to pharmaceutical
More informationIntroduction to Clinical Research
Introduction to Clinical Research What is Clinical Research? Clinical research is medical research that involves people like you. People volunteer to participate in carefully conducted investigations that
More informationFlorida State University Policy 7-IRB-
Florida State University Policy 7-IRB- Title of Policy: Institutional Review Board Jurisdiction/Applicability Responsible Executive: Gary K. Ostrander Approving Official: Gary K. Ostrander Effective Date:
More informationNational Study of Nephrotic Syndrome (NephroS) Information Sheet for Adult Patients
National Study of Nephrotic Syndrome (NephroS) Information Sheet for Adult Patients You are being invited to participate in a research study. Before you decide, it is important for you to understand why
More informationPackage leaflet: Information for the user. HUMAN ALBUMIN BAXALTA 200 g/l Solution for Infusion. Human albumin
Package leaflet: Information for the user HUMAN ALBUMIN BAXALTA 200 g/l Solution for Infusion Human albumin Read all of this leaflet carefully before you start using this medicine because it contains important
More informationThe Need for National Pharmacovigilance Program
The Need for National Pharmacovigilance Program ANAS BAHNASSI Presented at Order of Lebanese Pharmacists on March 10 th 2018 All drugs are dangerous Some are also useful. N. Moore, BMJ, 2005, 330;539-540
More informationThis talk will cover. Treatment for relapsed and/or refractory myeloma. What is relapsed myeloma and refractory myeloma. Treatment options for relapse
This talk will cover Treatment for relapsed and/or refractory myeloma Dr Guy Pratt Consultant Haematologist Heart of England NHS Trust and Senior Lecturer in Haematology University of Birmingham What is
More informationAnnex VIIIB Paragraphs to be included in the Informed Consent Form for the collection and use of biological samples in clinical trials
DEPARTAMENTO DE MEDICAMENTOS DE USO HUMANO Annex VIIIB Paragraphs to be included in the Informed Consent Form for the collection and use of biological samples in clinical trials Version 20 th December
More information1 - General FAQs about the Ebola virus (pages 1-3)
EBOLA FAQs This document contains three sections of FAQs: 1 - General FAQs about the Ebola virus (pages 1-3) 2 - FAQ for staff who may be meeting guests arriving from infected areas who ve been invited
More informationClinical trial information leaflet and consent
Informed consent 1(7) Clinical trial information leaflet and consent General You must provide sufficient information on the rights of clinical trial subjects, the purpose and nature of the trial, the methodologies
More informationSWOG ONCOLOGY RESEARCH PROFESSIONAL (ORP) MANUAL STUDY PROTOCOL CHAPTER 14 REVISED: OCTOBER 2015
THE STUDY PROTOCOL The study protocol is a written document detailing how a clinical trial is conducted. The elements of a protocol include: 1. Trial design and organization; 2. Study objectives; 3. Background
More informationIron Deficiency Anemia
Iron Deficiency Anemia Information for patients and families Read this brochure to learn: About Iron Deficiency Anemia Oral Iron Supplementation Intravenous Iron What is iron deficiency? Iron deficiency
More informationBios 6648: Design & conduct of clinical research
Bios 6648: Design & conduct of clinical research Section 3 - Essential principle (randomization) 3.4 Trial monitoring: Interim decision and group sequential designs Bios 6648- pg 1 (a) Recruitment and
More informationParticipant Copy. No. Participation is voluntary. Your decision will not affect your health care at Mayo Clinic in any way.
Name and Clinic Number IRB # 08-007049 00 Consent form approved July 16, 2015; This consent valid through July 15, 2016; 1. General Information About This Research Study Study Title: Mayo Clinic Biobank
More informationUnderstanding clinical research trials
Understanding clinical research trials Dr. Isabelle Fleury Medical Hemato-oncologist Hôpital Maisonneuve-Rosemont CIUSSS de l Est-de-l Île-de-Montréal Goals of this presentation Better understand clinical
More informationUnpacking Expanded Access to Investigational Drugs and Biologics
Unpacking Expanded Access to Investigational Drugs and Biologics When All Else Fails Richard Klein Office of Health and Constituent Affairs Food and Drug Administration September 13, 2016 FDA Drug Approval
More informationCompliance vs. Communication in Clinical Trial Registries
Vol. 1, No. 11, November 2005 Can You Handle the Truth? Compliance vs. Communication in Clinical Trial Registries By Mark Hochhauser Abstract The 1997 FDA Modernization Act called for a clinical trial
More informationLast Revised: 3/2018 Prior Version: 12/2014 SOP NUMBER: SS-304 Page 1 of 4
STANDARD OPERATING PROCEDURE (SOP) FOR CLINICAL RESEARCH Title: Investigational Drug Billing Last Revised: 3/2018 Prior Version: 12/2014 SOP NUMBER: SS-304 Page 1 of 4 1. PURPOSE: To assure accurate and
More informationFINDING THE RIGHT CULTURE FOR A REWARDING CAREER. A Guide for Registry and Data Quality Professionals
FINDING THE RIGHT CULTURE FOR A REWARDING CAREER A Guide for Registry and Data Quality Professionals Healthcare and the Burnout Factor You may have entered the healthcare profession because it is a growing
More informationpan-canadian Oncology Drug Review Patient Advocacy Group Feedback on a pcodr Expert Review Committee Initial Recommendation
pan-canadian Oncology Drug Review Patient Advocacy Group Feedback on a pcodr Expert Review Committee Initial Recommendation Ixazomib (Ninlaro) for Multiple Myeloma Myeloma Canada June 29, 2017 1. Feedback
More informationGenentech Contacts: Media: Tara Cooper (650) Investor: Kathee Littrell (650)
NEWS RELEASE Genentech Contacts: Media: Tara Cooper (650) 225-5505 Investor: Kathee Littrell (650) 225-1034 XOMA Media/Investor Contacts: Laura Zobkiw (510) 204-7273 Peter Davis (510) 204-7231 FDA APPROVES
More informationNiemann Pick Disease Clinical Trials
1 Niemann Pick Disease Clinical Trials This is an exciting and enviable time for the NPD community with several clinical trials currently in the news. It can be a confusing time too as families try to
More informationROLE OF THE RESEARCH COORDINATOR Investigational New Drug Application-Sponsor Responsibilities 21CFR Part , subpart D
Clinical and Translational Science Institute / CTSI at the University of California, San Francisco Welcome to Online Training for Clinical Research Coordinators ROLE OF THE RESEARCH COORDINATOR Investigational
More informationBIOLOGIC MEDICATIONS IN THE TREATMENT OF IBD. crohnsandcolitis.ca
BIOLOGIC MEDICATIONS IN THE TREATMENT OF IBD crohnsandcolitis.ca BIOLOGIC MEDICATIONS IN THE TREATMENT OF IBD INFLAMMATION AND IMMUNITY IN CROHN S AND COLITIS Inflammation is the body s normal and natural
More informationTHE ETHICAL ISSUES IN RESEARCH INVOLVING HEALTHY VOLUNTEERS
THE ETHICAL ISSUES IN RESEARCH INVOLVING HEALTHY VOLUNTEERS Rianto Setiabudy Presented in the13 th FERCAP International Conference Bali, 19 November 2013 Disclosure The speaker has no conflicts of interest.
More informationJune 15, Adaptive Phase I Studies: The IRB Perspective Marilyn Teal, PharmD IRB Member, Schulman IRB
June 15, 2016 Adaptive Phase I Studies: The IRB Perspective Marilyn Teal, PharmD IRB Member, Schulman IRB About Schulman IRB Established in 1983 Superior audit history with FDA five consecutive audits
More informationCancer Center Clinical Trials Office
STANDARD OPERATING PROCEDURE MANAGEMENT OF EXPANDED ACCESS & TREATMENT USE PROTOCOLS SOP#: 2.3 Original Approval Date: 8/27/15 Version#: 2.0 Current revision Date: 2/20/18 1.0 PURPOSE/BACKGROUND Expanded
More informationMarketing Your Telehealth Program. A White Paper
Marketing Your Telehealth Program A White Paper Marketing Your Telehealth Program Many Telehealth networks were built on a premise from the movie Field of Dreams: If you build it, they will come. Telehealth
More informationPharmacovigilance in Oncology. Luis H. Camacho, MD, MPH Houston, USA
Pharmacovigilance in Oncology Luis H. Camacho, MD, MPH Houston, USA 5th European Biosimilar Congress - Valencia June 27-29, 2016 Disclosure Director, Center for Oncology and Blood Disorders. Secretary,
More informationEffective Date: April 19, 2018 TITLE: GUIDELINE FOR RADIATION SAFETY COMMITTEE REVIEW OF HUMAN RESEARCH STUDIES. Table of Contents
Version: 2 Page: 1 of 6 Table of Contents 1.0 Introduction... 2 1.1 Purpose... 2 1.2 Scope... 2 1.3 Definitions... 2 2.0 Initial Protocol Review... 2 3.0 Radiation Risk Language... 3 4.0 Non-radiological
More informationMyeloma Bone Disease Current and Future Treatment. A Publication of The Bone and Cancer Foundation
Myeloma Bone Disease Current and Future Treatment A Publication of The Bone and Cancer Foundation What Is Multiple Myeloma? Multiple Myeloma is a cancer that results from a malignant change in a particular
More informationStem Cell Uses and FDA Regulation
Stem cells have been called everything from cure-alls to miracle treatments. But don t believe the hype. Some unscrupulous providers offer stem cell products that are both unapproved and unproven. So beware
More informationRadiotherapy. used to treat only small areas that are causing particular problems.
Radiotherapy This Infosheet explains what radiotherapy is, how it is used in the treatment of myeloma, how it is given and what the possible side-effects of this treatment are. What is radiotherapy? Radiotherapy
More informationConsent Forms Wendy Doggett, June 28, 2012
Consent Forms Wendy Doggett, doggettw@ohsu.edu June 28, 2012 Today s topics Tips for consent form writing New consent form templates Consent Process, Consent Discussion http://www.hhs.gov/ohrp/policy/consent/
More information07/30/2013. Record of Revisions IRB Page 1 of 17
Current Protocol Version 7.1 (Continuing Review) Approved July 30, 2013 Version 7.1 (Amendment) September 6, 2012 Version 7.0 (Continuing Review) July 30, 2012 Version 6.0 (Continuing Review) July 30,
More informationannex 3. Template consent form for biobanking
annex 3. Template consent form for biobanking This template is based on Public Population Project in Genomics and Society (P3G) database resources. General considerations The information brochure and consent
More informationRestrooms Cell phones on silent/vibrate. Refreshments. Patient resource materials
Restrooms Cell phones on silent/vibrate Refreshments Patient resource materials This presentation should not replace discussions with your healthcare provider, but seeks to provide information and resources
More informationBIOLOGIC AND BIOSIMILAR MEDICATIONS
BIOLOGIC AND BIOSIMILAR MEDICATIONS IN THE TREATMENT OF IBD crohnsandcolitis.ca BIOLOGIC AND BIOSIMILAR MEDICATIONS IN THE TREATMENT OF IBD Crohn s disease and ulcerative colitis are the two main forms
More informationUse of immunotherapy for cancer treatment
Use of immunotherapy for cancer treatment Pre- and post-licensing considerations Professor Angela Thomas, Pediatric Hematologist Vice Chair Commission on Human Medicines Chair Clinical Trials, Biologicals
More information@ALSETF #EAP2015. Jess B. Rabourn CBI Expanded Access Conference July 22, 2015
How to Win Physician Collaboration Models for Advancing Access to Lifesaving Therapies @ALSETF #EAP2015 Jess B. Rabourn CBI Expanded Access Conference July 22, 2015 How to Win Now that we want Expanded
More informationAdverse Event Reporting: During the Study
Vol. 5, No. 8, August 2009 Can You Handle the Truth? Adverse Event Reporting: During the Study By S. Eric Ceh The reporting of adverse events (AEs) is a standard task for investigative sites involved in
More informationLeukemia / Bone Marrow Transplant (BMT) Program of British Columbia
Leukemia / Bone Marrow Transplant (BMT) Program of British Columbia Patient Education Manual Research Module 1. Leukemia/BMT Daycare Outpatient Unit 2. Cell Separator Unit (CSU) 3. Outpatient Clinics 4.
More informationataluren overview A New Approach to Genetic Disorders
ataluren overview A New Approach to Genetic Disorders Ataluren Scientific Background What is ataluren? Ataluren(formerly PTC124) is the first investigational therapy with the potential to enable the formation
More informationMEDICAL RESEARCH: A CONSUMER S GUIDE FOR PARTICIPATION
H e a l t h L a w y e r s P u b l i c I n f o r m a t i o n S e r i e s MEDICAL RESEARCH: A CONSUMER S GUIDE FOR PARTICIPATION...to serve as a public resource on selected healthcare legal issues From the
More informationINSPECTION OF INDEPENDENT ETHICS COMMITTEES (IEC) The Italian Experience
INSPECTION OF INDEPENDENT ETHICS COMMITTEES (IEC) The Italian Experience Umberto Filibeck Former Head of AIFA GCP Inspectorate and GCP Promotion Unit UNICRI Consultant for Projects on GCP of CTs in developing
More informationInsertion of Skin Tunnelled Central Venous Catheter (STC)
Insertion of Skin Tunnelled Central Venous Catheter (STC) This leaflet explains more about STC insertion, including the benefits, risks and any alternatives and what you can expect when you come to hospital.
More informationWhat s New in GCP? FDA Draft Guidance Details FIH Multiple Cohort Trials
Vol. 14, No. 10, October 2018 Happy Trials to You What s New in GCP? FDA Draft Guidance Details FIH Multiple Cohort Trials While multiple, concurrently accruing patient cohorts in first-in-human (FIH)
More informationMCW Office of Research Standard Operating Procedure
MCW Office of Research Standard Operating Procedure USE AND STORAGE OF INVESTIGATIONAL DRUGS AND BIOLOGICS Unit: Applies to: Human Research Protections Program (HRPP), Office of Research MCW/FH Faculty
More informationIntegrating Genomics in Family Medicine
Lehigh Valley Health Network LVHN Scholarly Works Department of Family Medicine Integrating Genomics in Family Medicine Brian Stello MD Lehigh Valley Health Network, Brian.Stello@lvhn.org Follow this and
More informationObjectives Discuss the importance of proper data collection. Identify the types of data collected for clinical trials. List potential source documents
Data Management in Clinical Trials Introduction to the Principles and Practice of Clinical Research January 24, 2011 Diane St. Germain, RN, MS, CRNP Nurse Consultant Division of Cancer Prevention National
More informationInternational Transfers of Personal Data at sanofi-aventis R & D
International Transfers of Personal Data at sanofi-aventis R & D Pierre-Yves Lastic, PhD Senior Director, Standards Management & Data Privacy Sanofi-aventis R&D CONFERENCE ON INTERNATIONAL TRANSFERS OF
More information